Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
Add more filters










Publication year range
1.
Comput Biol Med ; 174: 108391, 2024 May.
Article in English | MEDLINE | ID: mdl-38613887

ABSTRACT

BACKGROUND: Liquid chromatography-mass spectrometry (LC-MS)-based quantitative phosphoproteomics has been widely used to detect thousands of protein phosphorylation modifications simultaneously from the biological specimens. However, the complicated procedures for analyzing phosphoproteomics data has become a bottleneck to widening its application. METHODS: Here, we develop PhosMap, a versatile and scalable tool to accomplish phosphoproteomics data analysis. A standardized phosphorylation data format was created for data analyses, from data preprocessing to downstream bioinformatic analyses such as dimension reduction, differential phosphorylation analysis, kinase activity, survival analysis, and so on. For better usability, we distribute PhosMap as a Docker image for easy local deployment upon any of Windows, Linux, and Mac system. RESULTS: The source code is deposited at https://github.com/BADD-XMU/PhosMap. A free PhosMap webserver (https://huggingface.co/spaces/Bio-Add/PhosMap), with easy-to-follow fashion of dashboards, is curated for interactive data analysis. CONCLUSIONS: PhosMap fills the technical gap of large-scale phosphorylation research by empowering researchers to process their own phosphoproteomics data expediently and efficiently, and facilitates better data interpretation.


Subject(s)
Computational Biology , Phosphoproteins , Proteomics , Software , Proteomics/methods , Phosphoproteins/analysis , Phosphoproteins/metabolism , Computational Biology/methods , Humans , Phosphorylation , Mass Spectrometry/methods , Chromatography, Liquid/methods
2.
Comput Biol Med ; 171: 108113, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38368754

ABSTRACT

BACKGROUND: The emergence of single-cell technology offers a unique opportunity to explore cellular similarity and heterogeneity between precancerous diseases and solid tumors. However, there is lacking a systematic study for identifying and characterizing similarities at single-cell resolution. METHODS: We developed SIMarker, a computational framework to detect cellular similarities between precancerous diseases and solid tumors based on gene expression at single-cell resolution. Taking hepatocellular carcinoma (HCC) as a case study, we quantified the cellular and molecular connections between HCC and cirrhosis. Core analysis modules of SIMarker is publicly available at https://github.com/xmuhuanglab/SIMarker ("SIM" means "similarity" and "Marker" means "biomarkers). RESULTS: We found PGA5+ hepatocytes in HCC showed cirrhosis-like characteristics, including similar transcriptional programs and gene regulatory networks. Consequently, the genes constituting the gene expression program of these cirrhosis-like subpopulations were designated as cirrhosis-like signatures (CLS). Strikingly, our utilization of CLS enabled the development of diagnosis and prognosis biomarkers based on within-sample relative expression orderings of gene pairs. These biomarkers achieved high precision and concordance compared with previous studies. CONCLUSIONS: Our work provides a systematic method to investigate the clinical translational significance of cellular similarities between HCC and cirrhosis, which opens avenues for identifying similar paradigms in other categories of cancers and diseases.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Precancerous Conditions , Humans , Liver Neoplasms/diagnosis , Liver Neoplasms/genetics , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/genetics , Transcriptome , Liver Cirrhosis/diagnosis , Liver Cirrhosis/genetics , Biomarkers , Biomarkers, Tumor/genetics
3.
Environ Sci Pollut Res Int ; 30(51): 110204-110219, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37779121

ABSTRACT

Groundwater is important for human survival and development, particularly in arid and semi-arid regions. This study aimed to analyze the hydrochemical characteristics, influencing factors, and the impact of human activities on groundwater in the semi-arid plains of western Jilin Province, northwest China. The study collected 88 and 151 phreatic and confined water samples, respectively, which were analyzed for 13 water quality indicators using statistical and graphical methods. In order to investigate the impact of anthropogenic activities on water quality and health risks, the improved combined weighted water quality index (ICWQI) based on the entropy weight, criteria importance though inter-criteria correlation (CRITIC), the coefficient of difference method, subjective weight based on quality grading criteria, and the water quality index (WQI) were proposed to evaluate the water quality of the study area. Meanwhile, the human health risk assessment (HHRA) model was used to assess the risks of nitrate to the health of humans in different ages and sex categories. The results indicated that the groundwater in the study area was weakly alkaline and the main hydrochemical types in the phreatic and confined water were HCO3-·Ca-Mg and HCO3--Na. Rock weathering was the dominant process responsible for the generation of groundwater ions, the ions in groundwater primarily originate from the dissolution of halite, gypsum, and feldspar, while dolomitization promotes an increase in Mg2+. Human activities lead to an increase in NO3- in groundwater and have an impact on water quality and human health risks. The ICWQI method was found to yield more precise and rational assessments of water quality. Groundwater quality is primarily affected by nitrate ions. The areas in which groundwater nitrate posed a higher risk to human health were found to be mainly in the saline-alkali lands of Qian'an, Tongyu, and Zhenlai. Fertilizers, pesticides, and livestock farming activities contribute to the pollution of surface water. This surface contamination then infiltrates abandoned confined wells, leading to contamination of the confined aquifers. This study can improve the understanding of groundwater hydrochemical characteristics and the impact of human activities on groundwater in the study area. This study can also contribute to the study of groundwater in semi-arid regions.


Subject(s)
Groundwater , Water Pollutants, Chemical , Humans , Environmental Monitoring/methods , Nitrates/analysis , Water Pollutants, Chemical/analysis , Water Quality , China , Human Activities
4.
TH Open ; 7(2): e97-e104, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37101592

ABSTRACT

Background Factor XIa (FXIa) is an emerging therapeutic target, and FXIa inhibition is a promising mechanism to improve therapeutic index over current anticoagulants. Milvexian (BMS-986177/JNJ-70033093) is an oral small-molecule FXIa inhibitor. Objective Milvexian's antithrombotic efficacy was characterized in a rabbit arteriovenous (AV) shunt model of venous thrombosis and compared with the factor Xa inhibitor apixaban and the direct thrombin inhibitor dabigatran. Methods The AV shunt model of thrombosis was conducted in anesthetized rabbits. Vehicle or drugs were administered as intravenous bolus plus a continuous infusion. Thrombus weight was the primary efficacy endpoint. Ex vivo activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin time (TT) were measured as the pharmacodynamic responses. Results Milvexian dose dependently reduced thrombus weights by 34.3 ± 7.9, 51.6 ± 6.8 ( p < 0.01; n = 5), and 66.9 ± 4.8% ( p < 0.001; n = 6) versus vehicle at 0.25 + 0.17, 1.0 + 0.67, and 4.0 ± 2.68 mg/kg bolus + mg/kg/h infusion, respectively. Ex vivo clotting data supported a dose-dependent prolongation of aPTT (with 1.54-, 2.23-, and 3.12-fold increases from baseline upon the AV shunt start), but no changes in PT and TT. Dose-dependent inhibition in thrombus weight and clotting assays was also demonstrated for both apixaban and dabigatran as the references for the model validation. Conclusion Results demonstrate that milvexian is an effective anticoagulant for prevention of venous thrombosis in the rabbit model, which supports the utility of milvexian in venous thrombosis, as seen in the phase 2 clinical study.

5.
Article in English | MEDLINE | ID: mdl-35954956

ABSTRACT

As a numerical indicator, the pollution index of groundwater (PIG) has gained a great deal of popularity in quantifying groundwater quality for drinking purposes. However, its weight-determination procedure is rather subjective due to the absolute dependence on experts' experience. To make the evaluation results more accurate and convincing, two improved PIG models (CRITIC-PIG and Entropy-PIG) that integrate subjective weights and objective weights were designed, and they were employed to appraise groundwater suitability for drinking purposes in the northern part of Changchun City. A total of 48 water samples (34 unconfined water samples and 14 confined water samples) with abundances of Ca2+ and HCO3- were collected and tested to obtain the data for the analyses. The results showed that 60.4%, 47.9% and 60.4% of the water samples manifested insignificant pollution and were marginally potable based on the values of the PIG, CRITIC-PIG and Entropy-PIG, respectively. Though 48% of the water samples had different evaluation results, their level difference was mostly 1, which is relatively acceptable. The distribution maps of the three sets of PIG values demonstrated that the quality of groundwater was the best in Dehui City and the worst in Nongan County. Groundwater contamination in the study area was mainly caused by the high concentrations of TDS, TH, Fe3+, F- and NO3-, which not only came from geogenic sources but also anthropogenic sources.


Subject(s)
Drinking Water , Groundwater , Water Pollutants, Chemical , China , Drinking Water/analysis , Environmental Monitoring/methods , Groundwater/analysis , Water Pollutants, Chemical/analysis , Water Quality
6.
Am J Transl Res ; 14(6): 4104-4113, 2022.
Article in English | MEDLINE | ID: mdl-35836861

ABSTRACT

OBJECTIVE: To explore the value of psycho-cardiology intervention on psychological resilience in patients with chronic heart failure (CHF) and investigate the associated factors. METHODS: A retrospective study of 142 patients with CHF was carried out. These patients were admitted to the Department of Cardiology, Provincial Clinical Medical College of Fujian Medical University from January 2017 to January 2021. They were grouped according to intervention method, including 74 patients with psycho-cardiology intervention and 68 with conventional intervention. The psychological resilience and the levels of anxiety and depression before and after intervention were assessed with the Connor-Davidson resilience scale (CD-RISC), self-rating anxiety scale (SAS), and self-rating depression scale (SDS), respectively. The factors associated with psychological resilience in patients with CHF were observed. The relationship between psychological resilience and SAS scores before intervention was studied. RESULTS: Using multivariate logistic regression analysis, we found that age (OR (95% CI): 3.452 (0.862-4.872), P=0.015), gender (OR, (95% CI): 3.389 (0.872-5.023), P=0.035), SAS score (OR (95% CI) 5.433 (1.543-14.333), P=0.027) and SDS score (OR (95% CI): 5.654 (1.572-15.823), P=0.021) were factors associated with psychological resilience in patients with CHF (all P<0.05). The average CD-RISC scores were 56.55±8.89 points in patients with CHF. The psychological resilience was inversely correlated with SAS score (r=-0.450, P<0.001) and SDS scores (r=-0.401, P<0.001). The CD-RISC scores of the observation group after intervention were higher than before intervention and higher than the control group, while SAS and SDS scores were decreased (all P<0.05). CONCLUSION: Age, gender, SAS, and SDS scores are factors associated with psychological resilience in patients with CHF. Psychological resilience was inversely associated with both anxiety and depression. Psycho-cardiology intervention can improve patients' psychological resilience, and reduce their anxiety and depression.

7.
J Med Chem ; 65(15): 10419-10440, 2022 08 11.
Article in English | MEDLINE | ID: mdl-35862732

ABSTRACT

Activated factor XI (FXIa) inhibitors are promising novel anticoagulants with low bleeding risk compared with current anticoagulants. The discovery of potent FXIa inhibitors with good oral bioavailability has been challenging. Herein, we describe our discovery effort, utilizing nonclassical interactions to improve potency, cellular permeability, and oral bioavailability by enhancing the binding while reducing polar atoms. Beginning with literature-inspired pyridine N-oxide-based FXIa inhibitor 1, the imidazole linker was first replaced with a pyrazole moiety to establish a polar C-H···water hydrogen-bonding interaction. Then, structure-based drug design was employed to modify lead molecule 2d in the P1' and P2' regions, with substituents interacting with key residues through various nonclassical interactions. As a result, a potent FXIa inhibitor 3f (Ki = 0.17 nM) was discovered. This compound demonstrated oral bioavailability in preclinical species (rat 36.4%, dog 80.5%, and monkey 43.0%) and displayed a dose-dependent antithrombotic effect in a rabbit arteriovenous shunt model of thrombosis.


Subject(s)
Factor XIa , Pyridines , Animals , Anticoagulants/chemistry , Anticoagulants/pharmacology , Dogs , Drug Design , Factor XIa/metabolism , Pyridines/pharmacology , Rabbits , Rats
8.
Med Biol Eng Comput ; 60(1): 33-45, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34677739

ABSTRACT

Computerized interpretation of electrocardiogram plays an important role in daily cardiovascular healthcare. However, inaccurate interpretations lead to misdiagnoses and delay proper treatments. In this work, we built a high-quality Chinese 12-lead resting electrocardiogram dataset with 15,357 records, and called for a community effort to improve the performances of CIE through the China ECG AI Contest 2019. This dataset covers most types of ECG interpretations, including the normal type, 8 common abnormal types, and the other type which includes both uncommon abnormal and noise signals. Based on the Contest, we systematically assessed and analyzed a set of top-performing methods, most of which are deep neural networks, with both their commonalities and characteristics. This study establishes the benchmarks for computerized interpretation of 12-lead resting electrocardiogram and provides insights for the development of new methods. Graphical Abstract A community effort to assess and improve computerized interpretation of 12-lead resting electrocardiogram.


Subject(s)
Electrocardiography , Neural Networks, Computer , Diagnostic Errors , Humans , Rest
9.
Small ; 17(49): e2103537, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34655164

ABSTRACT

The thermal stability of high-efficiency organic photovoltaics (OPVs) is critical to the manufacturing of this technology. Therefore, targeted strategies and approaches shall be developed to improve efficiency and stability, simultaneously. Herein, a seleno twisted benzodiperylenediimides (TBD-PDI-Se) acceptor-doping strategy is taken advantage of to demonstrate the ternary bulk heterojunction OPVs with excellent stability, achieving outstanding power conversion efficiency of 14.43% and 17.25% based on PM6:IT-4F and PM6:Y6 ternary blend devices, respectively, which are superior to the corresponding binary devices. As evidenced by the active layer morphology, exciton dynamic study and the characterizations of the enabled device, the ternary blend device keeps nearly 90% original efficiency (t = 1000 h) under continuous constant heating at 140 °C. Furthermore, the application of acceptor as the third component in PBDB-T:ITIC, J71:ITIC, and PBDB-T:PC71 BM systems is also verified, proving the good universality of acceptor-doping ternary strategy.

10.
J Pharmacol Exp Ther ; 360(3): 466-475, 2017 03.
Article in English | MEDLINE | ID: mdl-28035006

ABSTRACT

Coagulation Factor XII (FXII) plays a critical role in thrombosis. What is unclear is the level of enzyme occupancy of FXIIa that is needed for efficacy and the impact of FXIIa inhibition on cerebral embolism. A selective activated FXII (FXIIa) inhibitor, recombinant human albumin-tagged mutant Infestin-4 (rHA-Mut-inf), was generated to address these questions. rHA-Mut-inf displayed potency comparable to the original wild-type HA-Infestin-4 (human FXIIa inhibition constant = 0.07 and 0.12 nM, respectively), with markedly improved selectivity against Factor Xa (FXa) and plasmin. rHA-Mut-inf binds FXIIa, but not FXII zymogen, and competitively inhibits FXIIa protease activity. Its mode of action is hence akin to typical small-molecule inhibitors. Plasma shift and aPTT studies with rHA-Mut-inf demonstrated that calculated enzyme occupancy for FXIIa in achieving a putative aPTT doubling target in human, nonhuman primate, and rabbit is more than 99.0%. The effects of rHA-Mut-inf in carotid arterial thrombosis and microembolic signal (MES) in middle cerebral artery were assessed simultaneously in rabbits. Dose-dependent inhibition was observed for both arterial thrombosis and MES. The ED50 of thrombus formation was 0.17 mg/kg i.v. rHA-Mut-inf for the integrated blood flow and 0.16 mg/kg for thrombus weight; the ED50 for MES was 0.06 mg/kg. Ex vivo aPTT tracked with efficacy. In summary, our findings demonstrated that very high enzyme occupancy will be required for FXIIa active site inhibitors, highlighting the high potency and exquisite selectivity necessary for achieving efficacy in humans. Our MES studies suggest that targeting FXIIa may offer a promising strategy for stroke prevention associated with thromboembolic events.


Subject(s)
Blood Coagulation , Factor XIIa/antagonists & inhibitors , Insect Proteins/pharmacology , Intracranial Embolism , Intracranial Thrombosis , Recombinant Fusion Proteins/pharmacology , Serum Albumin/pharmacology , Animals , Anticoagulants/pharmacology , Blood Coagulation/drug effects , Blood Coagulation/physiology , Fibrinolytic Agents/pharmacology , Intracranial Embolism/blood , Intracranial Embolism/drug therapy , Intracranial Thrombosis/blood , Intracranial Thrombosis/drug therapy , Models, Animal , Rabbits , Serum Albumin, Human
11.
J Pharmacol Exp Ther ; 360(3): 476-483, 2017 03.
Article in English | MEDLINE | ID: mdl-28035007

ABSTRACT

Factor XI (FXI) is an integral component of the intrinsic pathway of the coagulation cascade and plays a critical role in thrombus formation. Because its role in the pathogenesis of cerebral microembolic signals (MES) is unclear, this study used a potent and selective small molecule inhibitor of FXIa, compound 1, to assess the effect of FXI blockade in our recently established preclinical model of cerebral MES induced by FeCl3 injury of the carotid artery in male New Zealand White rabbits. Ascending doses of compound 1 were evaluated simultaneously for both carotid arterial thrombosis by a Doppler flowmeter and MES in the middle cerebral artery by a transcranial Doppler. Plasma drug exposure and pharmacodynamic responses to compound 1 treatment were also assessed. The effective dose for 50% inhibition (ED50) of thrombus formation was 0.003 mg/kg/h compound 1, i.v. for the integrated blood flow, 0.004 mg/kg/h for reduction in thrombus weight, and 0.106 mg/kg/h for prevention of MES. The highest dose, 3 mg/kg/h compound 1, achieved complete inhibition in both thrombus formation and MES. In addition, we assessed the potential bleeding liability of compound 1 (5 mg/kg/h, i.v., >1250-fold ED50 levels in arterial thrombosis) in rabbits using a cuticle bleeding model, and observed about 2-fold (not statistically significant) prolongation in bleeding time. Our study demonstrates that compound 1 produced a robust and dose-dependent inhibition of both arterial thrombosis and MES, suggesting that FXIa blockade may represent a novel therapeutic strategy for the reduction in MES in patients at risk for ischemic stroke.


Subject(s)
Anticoagulants/pharmacology , Blood Coagulation/drug effects , Carotid Artery Thrombosis , Factor XIa/antagonists & inhibitors , Intracranial Embolism , Animals , Blood Coagulation/physiology , Carotid Artery Thrombosis/blood , Carotid Artery Thrombosis/complications , Carotid Artery Thrombosis/diagnostic imaging , Carotid Artery Thrombosis/drug therapy , Disease Models, Animal , Drug Design , Injections, Intravenous , Intracranial Embolism/blood , Intracranial Embolism/diagnostic imaging , Intracranial Embolism/etiology , Intracranial Embolism/prevention & control , Male , Rabbits , Ultrasonography, Doppler, Transcranial/methods
12.
J Pharmacol Exp Ther ; 358(3): 405-12, 2016 09.
Article in English | MEDLINE | ID: mdl-27384071

ABSTRACT

Cerebral microembolic signal (MES) is an independent predictor of stroke risk and prognosis. The objective of this study is to assess the effects of apixaban, as a representative of the novel oral anticoagulant class, on a rabbit model of cerebral MES. A clinical transcranial Doppler ultrasound instrument was used to assess MESs in the middle cerebral artery in a 30% FeCl3-induced carotid arterial thrombosis model in male New Zealand White rabbits. Ascending doses of apixaban were evaluated as monotherapy and in combination with aspirin on both arterial thrombosis and MES. Pharmacokinetic and pharmacodynamic responses were also evaluated. The effective dose for 50% inhibition (ED50) of thrombus formation for monotherapy was 0.04 mg/kg per hour apixaban, i.v. (0.03 µM plasma exposure) for the integrated blood flow, 0.13 mg/kg per hour apixaban (0.10 µM plasma exposure) for thrombus weight, and 0.03 mg/kg per hour apixaban (0.02 µM plasma exposure) for MES. Dual treatment with aspirin (5 mg/kg, PO) and apixaban (0.015 mg/kg per hour, i.v.) resulted in a significant reduction in cerebral MES (P < 0.05) compared with monotherapy with either agent. Pharmacokinetic analysis of apixaban and pharmacodynamic assays using activated partial thromboplastin time (aPTT) and prothrombin time (PT) for apixaban- and arachidonic acid-induced platelet aggregation for aspirin were used to confirm the exposure-response relationships. In summary, our study demonstrates that apixaban in a concentration-dependent manner inhibits both arterial thrombosis and MES, suggesting a potential association between factor Xa (FXa) blockade and the reduction in MES in patients at risk of ischemic stroke.


Subject(s)
Anticoagulants/pharmacology , Brain/drug effects , Brain/pathology , Carotid Artery Thrombosis/drug therapy , Carotid Artery Thrombosis/pathology , Pyrazoles/pharmacology , Pyridones/pharmacology , Signal Transduction/drug effects , Animals , Anticoagulants/pharmacokinetics , Anticoagulants/therapeutic use , Male , Pyrazoles/pharmacokinetics , Pyrazoles/therapeutic use , Pyridones/pharmacokinetics , Pyridones/therapeutic use , Rabbits
13.
Thromb Res ; 145: 133-9, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27318768

ABSTRACT

Platelet activation plays a crucial role in hemostasis and thrombosis. Thrombin, the most potent stimulus of platelet activation, mediates platelet activation via the protease activated receptors (PARs). The platelet PAR repertoire in mediating thrombin's action differs across species. Only nonhuman primate (NHP) platelet activation is known to be similar to humans, mediated by PAR1 and PAR4, hence limiting translational in vivo studies of PAR's role in thrombosis and hemostasis to NHPs. Earlier studies have demonstrated a range of distinct in vitro activities of PAR1 and 4 in platelet activation yet the implications of these events in vivo is unclear. The objective of this study is to investigate and compare the roles of PAR1 and PAR4 in hemostasis and thrombosis in a relevant animal species. NHP models for pharmacokinetic, ex vivo platelet aggregation responses, FeCI3 injury-mediated arterial thrombosis and template bleeding were developed in Cynomolgus Macaques. Potent and selective small molecule antagonists of PAR1 and PAR4 were characterized in an array of in vitro assays, and subsequently examined head-to-head in the NHP models. Treatment of NHPs with antagonists of PAR1 or PAR4 both resulted in strong inhibition of ex vivo platelet aggregation. At doses that led to similar inhibition of platelet aggregation, animals treated with the PAR4 antagonist showed similar levels of anti-thrombotic efficacy, but longer bleeding times, compared to animals treated with the PAR1 antagonist. These findings suggest that PAR1 antagonism will likely produce a larger therapeutic index (ie. a larger anti-thrombotic efficacy over bleeding risk margin) than PAR4 antagonism.


Subject(s)
Hemorrhage/drug therapy , Platelet Activation/drug effects , Receptors, Thrombin/antagonists & inhibitors , Thrombosis/drug therapy , Animals , Hemorrhage/etiology , Macaca fascicularis
14.
Food Funct ; 7(7): 3102-10, 2016 Jul 13.
Article in English | MEDLINE | ID: mdl-27273301

ABSTRACT

Bovine α-lactalbumin (α-La) is a major food allergen found in milk and is characterized by high conformational stability because of its four disulfide bridges and being calcium bound. This study aimed to describe the influence of gamma irradiation on the structure and potential allergenicity of α-La. The prepared α-La was irradiated at doses of 1-10 kGy. The changes in structure were characterized through SDS-PAGE, circular dichroism spectroscopy, ultraviolet absorption spectroscopy, and fluorescence spectroscopy. The potential allergenicity of the irradiated α-La was evaluated in vitro through IgG/IgE inhibition ELISA and the human basophil KU812 degranulation assay. The results showed that the secondary and tertiary structures of α-La significantly changed and caused extensive protein denaturation and aggregation. IgG and IgE binding properties remarkably decreased, and the degranulation capacity of basophils weakened. The results suggested that structural damage of α-La induced by irradiation significantly reduces the potential allergenicity of α-La.


Subject(s)
Allergens/chemistry , Lactalbumin/chemistry , Milk/chemistry , Allergens/immunology , Allergens/radiation effects , Animals , Basophils/immunology , Calcium/chemistry , Cell Line, Tumor , Child, Preschool , Circular Dichroism , Disulfides/chemistry , Dose-Response Relationship, Radiation , Electrophoresis, Polyacrylamide Gel , Female , Food Hypersensitivity/immunology , Food Hypersensitivity/prevention & control , Food Irradiation , Gamma Rays , Humans , Immunoglobulin E/immunology , Immunoglobulin G/immunology , Infant , Lactalbumin/immunology , Lactalbumin/radiation effects , Male , Molecular Weight , Protein Binding , Protein Denaturation , Rabbits , Spectrometry, Fluorescence
16.
J Thromb Thrombolysis ; 34(2): 199-207, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22588534

ABSTRACT

A role for platelets in the pathogenesis of venous thrombosis was suggested by clinical and preclinical studies. However, examination of the platelet receptor, P2Y1, in this area has been limited. The goal of the current study was to examine effects of P2Y1 deletion, or selective antagonism with MRS2500, in oxidative venous thrombosis in mice. The P2Y12 antagonist, clopidogrel, was included as a reference agent. Anesthetized C57BL/6 or genetically modified mice underwent 3.5 or 5 % FeCl(3)-induced vena cava thrombosis. Pharmacokinetic properties of MRS2500 were defined for dose selection. Platelet aggregation and renal or tail bleeding times (BT) were measured to put antithrombotic effects into perspective. P2Y1 deletion significantly reduced (p < 0.001) venous thrombus weight by 74 % in 3.5 % FeCl(3) injury compared to P2Y1(+/+) littermates. MRS2500 (2 mg/kg, i.v.) significantly decreased (p < 0.001) thrombus weight 64 % in C57BL/6 mice. In the more severe 5 % FeCl(3)-induced injury model, thrombus weight significantly (p < 0.001) decreased 68 % in P2Y1(-/-) mice versus P2Y1(+/+) mice, and MRS2500 (2 mg/kg) was also beneficial (54 % decrease, p < 0.01). Renal BT doubled in P2Y1(-/-) versus P2Y1(+/+) mice, and increased threefold with MRS2500 compared to vehicle. Tail BT was markedly prolonged in P2Y1(-/-) mice (7.9X) and in C57BL/6 mice given MRS2500. The current study demonstrates that P2Y1 deletion or antagonism significantly reduced venous thrombosis in mice, suggesting that P2Y1 receptors play a role in the pathogenesis of venous thrombosis, at least in this species. However as with many antithrombotic agents the benefit comes at the potential price of an increase in provoked bleeding times.


Subject(s)
Deoxyadenine Nucleotides/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Receptors, Purinergic P2Y1/metabolism , Venae Cavae , Venous Thrombosis/drug therapy , Animals , Blood Platelets/metabolism , Chlorides/adverse effects , Chlorides/pharmacology , Ferric Compounds/adverse effects , Ferric Compounds/pharmacology , Gene Deletion , Mice , Mice, Knockout , Noxae/adverse effects , Noxae/pharmacology , Platelet Aggregation/drug effects , Platelet Aggregation/genetics , Receptors, Purinergic P2Y1/genetics , Venous Thrombosis/chemically induced , Venous Thrombosis/genetics
17.
Thromb Haemost ; 107(6): 1141-50, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22398951

ABSTRACT

Plasma kallikrein is a multifunctional serine protease involved in contact activation of coagulation. Deficiency in humans is characterised by prolonged activated partial thromboplastin time (aPTT); however, the balance between thrombosis and haemostasis is not fully understood. A study of plasma kallikrein-deficient mice revealed increased aPTT, without prolonged bleeding time. Prekallikrein antisense oligonucleotide (ASO) treatment in mice suggested potential for a positive therapeutic index. The current goal was to further define the role of plasma kallikrein in coagulation. Blood pressure and heart rate were normal in plasma kallikrein-deficient mice, and mice were completely protected from occlusion (100 ± 1.3% control flow) in 3.5% FeCl3 -induced arterial thrombosis versus heterozygotes (20 ± 11.4%) and wild-type littermates (8 ± 0%). Vessels occluded in 8/8 wild-type, 7/8 heterozygotes, and 0/8 knockouts. Anti-thrombotic protection was less pronounced in 5% FeCl3-induced arterial injury. Integrated blood flow was 8 ± 0% control in wild-type and heterozygotes, and significantly (p<0.01) improved to 43 ± 14.2% in knockouts. The number of vessels occluded was similar in all genotypes. Thrombus weight was significantly reduced in knockouts (-47%) and heterozygotes (-23%) versus wild-type in oxidative venous thrombosis. Average tail bleeding time increased modestly in knockout mice compared to wild-type. Average renal bleeding times were similar in all genotypes. These studies confirm and extend studies with prekallikrein ASO, and demonstrate that plasma kallikrein deletion prevents occlusive thrombus formation in mice with a minimal role in provoked bleeding. Additional support for the significance of the intrinsic pathway in the coagulation cascade is provided, as well as for a potential new anti-thrombotic approach.


Subject(s)
Hemostasis , Plasma Kallikrein/metabolism , Prekallikrein/metabolism , Thrombosis/prevention & control , Animals , Bleeding Time , Chlorides , Disease Models, Animal , Ferric Compounds , Hemorrhage/blood , Hemorrhage/genetics , Hemostasis/genetics , Heterozygote , Mice , Mice, Knockout , Oligonucleotides, Antisense/metabolism , Partial Thromboplastin Time , Phenotype , Plasma Kallikrein/genetics , Prekallikrein/genetics , Thrombosis/blood , Thrombosis/chemically induced , Thrombosis/genetics , Time Factors , Venous Thrombosis/blood , Venous Thrombosis/chemically induced , Venous Thrombosis/genetics , Venous Thrombosis/prevention & control
18.
Curr Mol Pharmacol ; 5(2): 264-71, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22122456

ABSTRACT

PPARγ-modulators, a class of anti-diabetic drugs as represented by thiazolidinediones (TZD), have been associated with cardiovascular risks in type-2 diabetes in humans but a similar liability has not been demonstrated in preclinical models. This gap between clinical and preclinical observations may reflect the lack of a translational model for cardiac safety assessment because preclinical efficacy for glycemic control for PPARγ-modulators is routinely conducted in animals with diabetic background while drug safety study is performed in young and health animals with little risk of heart failure, in contrast to the complex pathophysiological conditions of patients subjected to the treatment of TZDs. Therefore, some key steps are important to address this translational gap. First, it is essential to use an appropriate translational model that mimics most of human pathophysiology for the assessment of cardiovascular safety for TZDs. Second, it calls for the discovery of a translational biomarker (most likely a collection of biomarkers due to multiple risk factors contributed to the complex disease) to be able to sensitively detect the disease progression and in response to therapy. Specific examples are provided in this review for the use of a rodent model of myocardial infarction-induced heart failure to address the cardiac safety concern in response to chronic treatment of rosiglitazone. Multiple biomarkers, including physiological, biochemical, pharmacogenomic and imaging biomarkers, were applied to assess the cardiovascular risk in this heart failure model. The data and strategic approach are discussed from translational medicine perspectives.


Subject(s)
Heart Failure/etiology , Hypoglycemic Agents/adverse effects , PPAR gamma/agonists , Thiazolidinediones/adverse effects , Animals , Biomarkers/metabolism , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Disease Models, Animal , Gene Expression Profiling , Heart Failure/metabolism , Hypoglycemic Agents/therapeutic use , Kidney/metabolism , Myocardial Infarction/complications , PPAR gamma/metabolism , Rosiglitazone , Thiazolidinediones/therapeutic use , Translational Research, Biomedical
19.
J Pharmacol Exp Ther ; 339(2): 421-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21835932

ABSTRACT

The mammalian target of rapamycin (mTOR) has proven to be a valid therapeutic target in a number of human cancers, and it is a candidate for clinical trials in human breast cancer. We report on a biomarker-based translational medicine approach to assess the efficacy and mechanism of action for the mTOR inhibitor temsirolimus (CCI-779) in a mammary carcinoma OncoMouse model [polyomavirus middle T antigen (PyMT)]. The mTOR signaling pathway biomarkers were assessed using a reverse-phase protein array. Pharmacokinetics studies were conducted in both the tumor and plasma compartments. Pharmacodynamic biomarkers for compound-target engagement of tumor phospho-S6 proteins were assayed by Western blot. Temsirolimus (intravenously once a week for 2 weeks) was administered in both early and advanced stages of tumors. Biomarkers for temsirolimus effects on tumor progression were assessed by three-dimensional ultrasound imaging in combination with immunohistochemistry to assess vascular density (Texas red-dextran and CD31 immunostaining) and macrophage burden (F4/80 antigen). Tumor growth was significantly arrested in temsirolimus (25 ± 14% from 8 to 10 weeks, p < 0.05, and 26 ± 17% from 11 to 13 weeks, p < 0.01), compared with 493 ± 160 and 376 ± 50% increases, respectively, in vehicle-treated groups. Temsirolimus reduced tumor vascular density, 36 to 48 and 58 to 60%, p < 0.05, by the Texas red-dextran method or CD31-positive vessel count, respectively. Temsirolimus reduced tumor macrophage burden by 46% at 13 weeks (p < 0.05). Temsirolimus inhibited (p < 0.05) the phosphoproteins S6 pS235/236 and S6 pS240/244 up to 81 and 87%, respectively. We conclude that the multimodal biomarkers of temsirolimus efficacy and mechanism of action (phosphoproteins) strongly suggest that it might translate to therapeutic efficacy in human tumors that bear congruency to features present in the mammary carcinoma of PyMT tumors.


Subject(s)
Biomarkers, Pharmacological/analysis , Mammary Neoplasms, Experimental/drug therapy , Protein Kinase Inhibitors/pharmacology , Sirolimus/analogs & derivatives , TOR Serine-Threonine Kinases/antagonists & inhibitors , Tumor Burden/drug effects , Animals , Cell Line, Tumor , Disease Progression , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Female , Infusions, Intravenous , Mice , Mice, Transgenic , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/pharmacokinetics , Signal Transduction/drug effects , Sirolimus/administration & dosage , Sirolimus/pharmacokinetics , Sirolimus/pharmacology , TOR Serine-Threonine Kinases/analysis , Translational Research, Biomedical/methods , Xenograft Model Antitumor Assays
20.
Circ Heart Fail ; 4(3): 345-54, 2011 May.
Article in English | MEDLINE | ID: mdl-21398416

ABSTRACT

BACKGROUND: The side effects of fluid retention and edema of the thiazolidinedione (TZD) class of peroxisome proliferator-activated receptor-γ agonists limit their use in patients with congestive heart failure (CHF). The present study aims to explore whether chronic treatment with the TZD compound rosiglitazone (RGZ) is associated with worsening of salt and water retention in male Sprague-Dawley rats with aorto-caval fistula, an experimental model of volume-overload CHF. METHODS AND RESULTS: The effects of oral RGZ (30 mg/kg per day for 4 weeks) in CHF rats on plasma volume, cumulative sodium excretion, renal expression of Na(+) channels and transporters, and selected biomarkers of CHF were compared with those in CHF rats and sham-operated control rats treated with vehicle only (n=7 to 10). Additionally, the response to acute saline loading (3.5% of body weight) was evaluated after 2 weeks of treatment by renal clearance methodology. Chronic RGZ treatment caused no further increase in plasma volume compared with vehicle-treated CHF rats. Moreover, no increase in renal expression of Na(+) transport-linked channels/transporters was observed in response to RGZ. Cumulative sodium excretion was enhanced in CHF rats after RGZ and by another TZD compound, pioglitazone. In response to saline loading, RGZ-treated animals displayed a higher natriuretic/diuretic response than did vehicle-treated rats. Chronic RGZ treatment was not associated with any deterioration in selected biomarkers of CHF, whereas indices of cardiac hypertrophy and blood pressure were improved. CONCLUSIONS: Chronic RGZ treatment was not associated with worsening of fluid retention or cardiac status in rats with experimental volume-overload CHF. Rather, RGZ appeared to improve renal handling of salt and water in rats with CHF.


Subject(s)
Heart Failure/drug therapy , Thiazolidinediones/pharmacology , Water-Electrolyte Balance/drug effects , Water-Electrolyte Imbalance/drug therapy , Animals , Disease Models, Animal , Heart Failure/physiopathology , Kidney Function Tests , Male , Rats , Rats, Sprague-Dawley , Rosiglitazone , Sodium Chloride/metabolism , Thiazolidinediones/therapeutic use , Water/metabolism , Water-Electrolyte Imbalance/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...